Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)

Market Cap	15.53B
Revenue (ttm)	2.50B
Net Income (ttm)	654.13M
Shares Out	950.40M
EPS (ttm)	0.70
PE Ratio	23.50
Forward PE	14.21
Dividend	0.38 (2.35%)
Ex-Dividend Date	Jun 4, 2025

Volume	9,450,442
Average Volume	8,845,666
Open	16.30
Previous Close	16.39
Day's Range	16.28 - 16.58
52-Week Range	15.32 - 20.00
Beta	0.59
RSI	35.28
Earnings Date	Oct 28, 2025

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), freeze-dried intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor vin. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,635
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2024, SHE:000403's revenue was 2.65 billion, an increase of 14.00% compared to the previous year's 2.33 billion. Earnings were 745.32 million, an increase of 21.76%.